← Back to headlines
AstraZeneca Stock Falls After FDA Panel Votes Against New Cancer Drug
AstraZeneca PLC's stock experienced a decline after an FDA panel voted against the approval of its new cancer drug.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
